Pressure BioScience (PBIO) could be an Important Company in Cancer Moonshot
Alliance Health (AIQ): A Leader in Radiology in an Aging Society
Your Favorite Brands Have Sneakily Been Reducing Package Sizes
Selling Shovels at the Gold Rush: Heliospectra’s (HLSPY) Lights are the tool Cannabis Growers Need
Should Commodities Be in Your Portfolio?
David Mazzo of Regado Biosciences talks to Equities.com about the company's novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.
You have to be logged in to leave a comment.
I'm sorry, but in order to complete what you're trying to do, you must be logged in.
© 2016 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).